

Jane J Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7129841/publications.pdf>

Version: 2024-02-01

103
papers

5,236
citations

101543

36
h-index

95266

68
g-index

104
all docs

104
docs citations

104
times ranked

5209
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 228.e1-228.e9.	1.3	8
2	Switching clinic-based cervical cancer screening programs to HPV self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women. <i>International Journal of Cancer</i> , 2022, 150, 491-501.	5.1	7
3	Potential effectiveness of a therapeutic HPV intervention campaign in Uganda. <i>International Journal of Cancer</i> , 2022, 150, 847-855.	5.1	2
4	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. <i>Vaccine</i> , 2022, 40, 76-88.	3.8	15
5	Impact of Delaying Effective and Cost-Effective Policy Decisions: An Example From Cervical Cancer Prevention in Norway. <i>MDM Policy and Practice</i> , 2022, 7, 238146832110710.	0.9	0
6	Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis. <i>Medical Decision Making</i> , 2022, 42, 795-807.	2.4	3
7	Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting. <i>International Journal of Cancer</i> , 2022, 151, 1804-1809.	5.1	4
8	Different human papillomavirus types share early natural history transitions in immunocompetent women. <i>International Journal of Cancer</i> , 2022, 151, 920-929.	5.1	5
9	Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries. <i>International Journal of Cancer</i> , 2021, 148, 932-940.	5.1	18
10	Given a choice between self-sampling at home for HPV testing and standard of care screening at the clinic, what do African American women choose? Findings from a group randomized controlled trial. <i>Preventive Medicine</i> , 2021, 142, 106358.	3.4	11
11	Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1114-1121.	2.5	7
12	Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis. <i>Preventive Medicine</i> , 2021, 144, 106276.	3.4	18
13	A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. <i>Preventive Medicine</i> , 2021, 144, 106438.	3.4	20
14	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2021, 18, e1003534.	8.4	30
15	Health gains and financial protection from human papillomavirus vaccination in Ethiopia: findings from a modelling study. <i>Health Policy and Planning</i> , 2021, 36, 891-899.	2.7	5
16	Cost-utility analysis of heart surgeries for young adults with severe rheumatic mitral valve disease in India. <i>International Journal of Cardiology</i> , 2021, 338, 50-57.	1.7	3
17	Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validation. <i>Preventive Medicine</i> , 2021, 150, 106688.	3.4	1
18	Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis. <i>Preventive Medicine</i> , 2021, 151, 106623.	3.4	34

#	ARTICLE	IF	CITATIONS
19	Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 955-963.	6.3	37
20	The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. <i>Preventive Medicine</i> , 2020, 131, 105931.	3.4	9
21	Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 321-346.	329.8	481
22	Historical and projected hysterectomy rates in the USA: Implications for future observed cervical cancer rates and evaluating prevention interventions. <i>Gynecologic Oncology</i> , 2020, 158, 710-718.	1.4	16
23	Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 22-30.	2.5	5
24	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). <i>British Journal of Cancer</i> , 2020, 123, 510-517.	6.4	74
25	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 575-590.	13.7	421
26	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 591-603.	13.7	321
27	Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis. <i>International Journal of Cancer</i> , 2019, 144, 687-696.	5.1	11
28	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100184.	4.5	41
29	The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 40-46.	2.3	20
30	Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3138-3145.	3.3	21
31	Health and Economic Impact of Intensive Surveillance for Distant Recurrence After Curative Treatment of Colon Cancer: A Mathematical Modeling Study. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 872-881.	1.3	4
32	Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. <i>International Journal of Cancer</i> , 2019, 144, 1460-1473.	5.1	20
33	Trends of two HPV-associated cancers in Massachusetts: cervical and oropharyngeal cancer. <i>Cancer Causes and Control</i> , 2018, 29, 435-443.	1.8	3
34	An overview of cervical cancer epidemiology and prevention in Scandinavia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 795-807.	2.8	38
35	Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines. <i>European Journal of Cancer</i> , 2018, 91, 68-75.	2.8	45
36	Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 158-164.	2.5	36

#	ARTICLE	IF	CITATIONS
37	Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 195-205.	2.1	19
38	Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial. <i>BMJ Open</i> , 2018, 8, e020484.	1.9	38
39	Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 10-19.	2.1	2
40	Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. <i>Vaccine</i> , 2018, 36, 4823-4829.	3.8	42
41	Legislation to Increase Uptake of HPV Vaccination and Adolescent Sexual Behaviors. <i>Pediatrics</i> , 2018, 142, .	2.1	16
42	Screening for Cervical Cancer in Primary Care. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 706.	7.4	112
43	Bayesian Methods for Calibrating Health Policy Models: A Tutorial. <i>Pharmacoeconomics</i> , 2017, 35, 613-624.	3.3	42
44	Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. <i>BMJ Open</i> , 2017, 7, e015048.	1.9	29
45	Cervical cancer prevention in El Salvador (CAPE)â€”An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country. <i>Gynecologic Oncology Reports</i> , 2017, 20, 58-61.	0.6	17
46	Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting. <i>Health Policy and Planning</i> , 2017, 32, 956-968.	2.7	15
47	To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings. <i>International Journal of Cancer</i> , 2017, 140, 1293-1305.	5.1	20
48	The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 47-56.	2.3	50
49	Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings. <i>Cancer Medicine</i> , 2017, 6, 2008-2014.	2.8	22
50	The Cost-Effectiveness of Visual Triage of Human Papillomavirusâ€”Positive Women in Three Low- and Middle-Income Countries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1500-1510.	2.5	13
51	Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway. <i>British Journal of Cancer</i> , 2017, 117, 783-790.	6.4	14
52	Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. <i>Journal of Global Oncology</i> , 2017, 3, 635-657.	0.5	121
53	Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw216.	6.3	72
54	Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 709-717.	0.8	31

#	ARTICLE	IF	CITATIONS
55	The Cost-Effectiveness of Cervical Self-Sampling to Improve Routine Cervical Cancer Screening: The Importance of Respondent Screening History and Compliance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 95-103.	2.5	23
56	Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study. <i>BMC Cancer</i> , 2017, 17, 791.	2.6	26
57	Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer. <i>Clinical Infectious Diseases</i> , 2017, 65, 893-899.	5.8	58
58	Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. <i>Pharmacoeconomics</i> , 2016, 34, 913-923.	3.3	136
59	Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. <i>American Journal of Preventive Medicine</i> , 2016, 51, 507-512.	3.0	46
60	Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. <i>Gynecologic Oncology</i> , 2016, 143, 326-333.	1.4	18
61	Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs. <i>Cancer</i> , 2016, 122, 1338-1342.	4.1	20
62	Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. <i>Journal of General Internal Medicine</i> , 2016, 31, 372-379.	2.6	34
63	Costs and cost-effectiveness of a mental health intervention for war-affected young persons: decision analysis based on a randomized controlled trial. <i>Health Policy and Planning</i> , 2016, 31, 415-424.	2.7	18
64	Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines. <i>Journal of General Internal Medicine</i> , 2016, 31, 52-59.	2.6	78
65	When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 38-58.	4.5	42
66	Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. <i>International Journal of Cancer</i> , 2015, 137, 2208-2219.	5.1	49
67	Letter to the Editor Regarding "Evaluation of a Cervicography-Based Program to Ensure Quality of Visual Inspection of the Cervix in HIV-Infected Women in Johannesburg, South Africa" by Firnhaber et al. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, e45-e46.	1.9	1
68	Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia. <i>PLoS ONE</i> , 2015, 10, e0140930.	2.5	46
69	The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. <i>International Journal of Cancer</i> , 2015, 137, 893-902.	5.1	38
70	Unifying Screening Processes Within the PROSPR Consortium: A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv120-djv120.	6.3	76
71	Too Late to Vaccinate? The Incremental Benefits and Cost-effectiveness of a Delayed Catch-up Program Using the 4-Valent Human Papillomavirus Vaccine in Norway. <i>Journal of Infectious Diseases</i> , 2015, 211, 206-215.	4.0	27
72	An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. <i>Vaccine</i> , 2015, 33, 2830-2841.	3.8	54

#	ARTICLE	IF	CITATIONS
73	Improving outcomes for caregivers through treatment of young people affected by war: a randomized controlled trial in Sierra Leone. <i>Bulletin of the World Health Organization</i> , 2015, 93, 834-841.	3.3	9
74	Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys. <i>PLoS ONE</i> , 2014, 9, e89974.	2.5	74
75	Practice-Based Evidence for Primary HPV Testing in the United States. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju213-dju213.	6.3	3
76	An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters. <i>American Journal of Epidemiology</i> , 2014, 180, 545-555.	3.4	87
77	Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries. <i>PLoS ONE</i> , 2014, 9, e106836.	2.5	25
78	Determining optimal first-line chemotherapy for good and intermediate prognosis testicular germ cell tumors using decision analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 209-209.	1.6	0
79	Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. <i>Vaccine</i> , 2013, 31, H71-H79.	3.8	18
80	Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan Africa. <i>Vaccine</i> , 2013, 31, F60-F72.	3.8	35
81	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, H1-H31.	3.8	272
82	Recommendations for Cervical Cancer Prevention in Sub-Saharan Africa. <i>Vaccine</i> , 2013, 31, F73-F74.	3.8	29
83	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, F1-F31.	3.8	40
84	Extended Middle East and North Africa: Summary Recommendations for the Prevention of Human Papillomavirus Infections and Related Cancers Including Cervical Cancer. <i>Vaccine</i> , 2013, 31, G78-G79.	3.8	2
85	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, G1-G31.	3.8	33
86	Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in the Extended Middle East and North Africa (EMENA). <i>Vaccine</i> , 2013, 31, G65-G77.	3.8	37
87	Cost-effectiveness analysis of proton versus photon therapy with respect to risk of growth hormone deficiency.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17553-e17553.	1.6	0
88	Policy Implications of Adjusting Randomized Trial Data for Economic Evaluations. <i>Medical Decision Making</i> , 2012, 32, 400-427.	2.4	3
89	Opportunities to Improve Cervical Cancer Screening in the United States. <i>Milbank Quarterly</i> , 2012, 90, 38-41.	4.4	4
90	The Role of Cost-Effectiveness in U.S. Vaccination Policy. <i>New England Journal of Medicine</i> , 2011, 365, 1760-1761.	27.0	42

#	ARTICLE	IF	CITATIONS
91	Weighing the Benefits and Costs of HPV Vaccination of Young Men. <i>New England Journal of Medicine</i> , 2011, 364, 393-395.	27.0	36
92	Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 845-852.	9.1	159
93	Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. <i>BMJ: British Medical Journal</i> , 2009, 339, b3884-b3884.	2.3	189
94	Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States. <i>Annals of Internal Medicine</i> , 2009, 151, 538.	3.9	81
95	Exploring the cost-effectiveness of HPV vaccination in Vietnam: Insights for evidence-based cervical cancer prevention policy. <i>Vaccine</i> , 2008, 26, 4015-4024.	3.8	53
96	Modeling Cervical Cancer Prevention in Developed Countries. <i>Vaccine</i> , 2008, 26, K76-K86.	3.8	102
97	Health and Economic Implications of HPV Vaccination in the United States. <i>New England Journal of Medicine</i> , 2008, 359, 821-832.	27.0	317
98	Multiparameter Calibration of a Natural History Model of Cervical Cancer. <i>American Journal of Epidemiology</i> , 2007, 166, 137-150.	3.4	131
99	Cost-Effectiveness Analysis of Treatment Strategies for Stage I and II Endometrial Cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007, 29, 131-139.	0.7	20
100	Packaging Health Services When Resources Are Limited: The Example of a Cervical Cancer Screening Visit. <i>PLoS Medicine</i> , 2006, 3, e434.	8.4	26
101	Mathematical Model of HPV Provides Insight into Impacts of Risk Factors and Vaccine. <i>PLoS Medicine</i> , 2006, 3, e164.	8.4	7
102	Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy. <i>Journal of the National Cancer Institute</i> , 2005, 97, 888-895.	6.3	106
103	Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. <i>Journal of Public Health</i> , 2004, 26, 130-137.	1.8	30